Cargando…
Efficacy and Safety of Setmelanotide, a Melanocortin-4 Receptor Agonist, for Obese Patients: A Systematic Review and Meta-Analysis
Background: A malfunction in the melanocortin-4 receptor (MC4R) is associated with obesity in rare genetic syndromes; setmelanotide is a new drug that activates this receptor and is being used to treat severe obesity. This meta-analysis evaluated the efficacy and safety of setmelanotide for weight l...
Autores principales: | Ferraz Barbosa, Bárbara, Aquino de Moraes, Francisco Cezar, Bordignon Barbosa, Camila, Palavicini Santos, Plínio Takashi Karubi, Pereira da Silva, Izael, Araujo Alves da Silva, Bruno, Cristine Marques Barros, Jamile, Rodríguez Burbano, Rommel Mario, Pereira Carneiro dos Santos, Ney, Rodrigues Fernandes, Marianne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10608339/ https://www.ncbi.nlm.nih.gov/pubmed/37888071 http://dx.doi.org/10.3390/jpm13101460 |
Ejemplares similares
-
Effect of setmelanotide, a melanocortin‐4 receptor agonist, on obesity in Bardet‐Biedl syndrome
por: Haws, Robert, et al.
Publicado: (2020) -
Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency
por: Collet, Tinh-Hai, et al.
Publicado: (2017) -
Structures of active melanocortin-4 receptor–Gs-protein complexes with NDP-α-MSH and setmelanotide
por: Heyder, Nicolas A., et al.
Publicado: (2021) -
Setmelanotide, a Novel, Selective Melanocortin Receptor-4 Agonist Exerts Anti-inflammatory Actions in Astrocytes and Promotes an Anti-inflammatory Macrophage Phenotype
por: Kamermans, Alwin, et al.
Publicado: (2019) -
A Phase 3 Trial in Participants With Obesity Due to Bardet-Biedl Syndrome or Alström Syndrome: Efficacy and Safety of the Melanocortin 4 Receptor Agonist Setmelanotide
por: Haws, Robert, et al.
Publicado: (2021)